Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Post by Francine01on Jun 04, 2019 9:54am
53 Views
Post# 29796709

Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100

Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100

More than 60% of patients have completed their 6-month treatment plan

Topline results remain on track for year-end

LAVAL, Quebec, June 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s TRILOGY 2 trial studying CaPre in patients with severe hypertriglyceridemia has achieved 100% patient randomization.  This follows the Company’s prior announcement in April 2019 that the Company’s TRILOGY 1 trial had achieved 100% patient randomization.

The Company also announced that its two on-going Phase 3 TRILOGY trials (TRILOGY 1 and TRILOGY 2) have exceeded the target of a combined 500 randomized patients, and more than 60% of the patients in both trials have already completed their 6-month treatment plan.  

The fact that both studies have now reached full randomization means that the “last patient, last visit” in the TRILOGY 1 trial is on track to take place in November, and the “last patient, last visit” in the TRILOGY 2 trial is on track to take place in December. It is then anticipated to take approximately 1 month for data clean-up prior to moving to database lock.  Once the database is locked, the Company expects topline results for TRILOGY 1 to be released in December 2019 and TRILOGY 2 to be released in January 2020. Topline results will include readout of the primary endpoint, which will show CaPre’s overall impact on lowering triglycerides after 12 weeks. In addition, the topline results will include CaPre’s impact on several important secondary endpoints such as LDL, VLDL and HDL cholesterol and non-HDL cholesterol, as well as HbA1c, an exploratory endpoint which is an important biomarker of glucose control for diabetic patients. The full data set will include results on a number of additional lipid, metabolic and inflammatory markers including CRP, APOA1, APOB, APOA5, APOC3, Lp-PLA2, PCSK9, RLP-C and others. The Company plans to submit the full data set as a late breaker presentation at the American College of Cardiology at the end of March 2020.

Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “Both of our TRILOGY Phase 3 trials remain on track and are proceeding according to plan. Consistent with our prior disclosures, there have been no severe adverse events associated with our product to date, and we continue to experience a lower than expected drop-out rate, supporting the high safety profile and patient acceptability of CaPre. Importantly, we are encouraged by the growing excitement within the industry as we eagerly await the results of our TRILOGY program.  We appreciate the on-going support of all of the investigators involved with these trials at more than 150 clinical sites across the U.S., Canada, and Mexico.”  

About CaPre (omega-3 phospholipid)

Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body. Acasti believes that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the EPA and DHA contained in fish oil that are transported either by triglycerides (as in dietary supplements) or as ethyl esters in other prescription omega-3 drugs, which must then undergo additional digestion before they are ready for transport in the bloodstream. Clinically, the phospholipids may not only improve the absorption, distribution, and metabolism of omega-3s, but they may also decrease the synthesis of LDL cholesterol in the liver, impede or block cholesterol absorption, and stimulate lipid secretion from bile. In two Phase 2 studies, CaPre achieved a statistically significant reduction of triglycerides and non-HDL cholesterol levels in patients across the dyslipidemia spectrum from patients with mild to moderate hypertriglyceridemia (patients with TG blood levels between 200mg/dl and 500mg/dl) to patients with severe hypertriglyceridemia (those with TG levels above 500mg/dl). Furthermore, in the Phase 2 studies, CaPre demonstrated the potential to reduce LDL, or “bad cholesterol”, as well as the potential to increase HDL, or “good cholesterol”, especially at the therapeutic dose of 4 grams/day. The Phase 2 data also showed a significant reduction of HbA1c at a 4 gram dose, suggesting that due to its unique omega-3/phospholipid composition, CaPre may actually improve long-term glucose metabolism. Acasti’s TRILOGY Phase 3 program is currently underway.


<< Previous
Bullboard Posts
Next >>